Interim report 9M
2022-11-04 @ 08:00 - 10:00
Report will be released at 08:00am CET and conference call at 10:00am CET
About us
Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway.
Headquarter is in Malmö, Sweden, and the company’s shares are listed on Nasdaq Stockholm (ticker: ACE)
Download our fact sheet: Ascelia Pharma Factsheet Dec 2020
Latest presentations
Q2 2021 presentation (pdf), link to webcast
Latest news
- 2021-09-21Ascelia Pharma Signs Clinical Collaboration Agreement With Taiho Oncology, Inc. for the Development of Oncoral in Combination with LONSURF®
- 2021-08-19Quarterly Report Q2 2021: Preparing Oncoral for the next level
- 2021-08-18Covid-19 extends recruitment period of SPARKLE study
- 2021-08-13Abstract for Orviglance comparison study to gadolinium accepted at the world’s largest radiology conference RSNA
- 2021-08-10Ascelia Pharma receives conditional FDA acceptance for brand name Orviglance
Events
- September 27 @ 12:30 - 13:00
Magnus Corfitzen CEO at Ascelia Pharma will present at HC Andersen Capital
- September 28 @ 11:00 - 11:30
Chief Medical Officer Carl Bjartmar will present Ascelia Pharma at Aktiespararna in Lund
- September 30 @ 10:05 - 10:45
Magnus Corfitzen CEO at Ascelia Pharma will present at Erik Penser Bank Orphan Drugs’s Day
- October 5 @ 11:00 - 11:45
Danske Bank Event Series: Life Science, Launch Phase
- November 4 @ 08:00
Interim report 9M (January-September 2021)